RxDoctor Payments Data

Sudha Pandit, MD

Gastroenterology · Shreveport, LANPI 1548601222

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.2% of the total across 383 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 27.6% of the total. 2025 is the largest year on record at $1,960, 3.7 times the $531 reported in 2019.

$7,762in general payments, 2019–2025

Across 383 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$815
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$718
  • Johnson & Johnson$712
  • Medtronic$660
  • Pfizer$572
  • plus $2K from 22 others
$15,000in research payments, 2019–2025

Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$15K

What the payments were for

  • Consulting fees$6609%
  • Food & beverage$7,00490%
  • Education$701%
  • Gifts$270%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,762 in reported general payments places this provider in the 70th percentile of 254 gastroenterology providers in Louisiana.

See all gastroenterology providers in Louisiana

Medicare billing

Part B allowed, 2024
$39,527
Medicare patients
194
Services billed
376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates31$2,054
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl77$1,245
Sucralfate11$1,098
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl30$496
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl31$496
Omeprazole12$190
Pantoprazole Sodium19$81

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →